Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab
Authors:
- 3 May 2025
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 24 (7) , 103826
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82071410, 82001335)
- Innovative Research Group Project of the National Natural Science Foundation of China
- Shanghai Municipal Hospital Development Center (SHDC2023CRD007)
This publication has 126 references indexed in Scilit:
- Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-κB/IL-6 signaling pathwayCellular and Molecular Life Sciences, 2022
- Characterization and Function of Tumor Necrosis Factor and Interleukin‐6–Induced Osteoclasts in Rheumatoid ArthritisArthritis & Rheumatology, 2021
- The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in InflammationClinical Pharmacology & Therapeutics, 2017
- Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatmentMuscle & Nerve, 2016
- Interleukin‐6 Receptor Blockade Enhances CD39+ Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental ArthritisArthritis & Rheumatology, 2013
- Aquaporin 4‐specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporterAnnals of Neurology, 2012
- Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanismsAnnals of Neurology, 2011
- Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravisAnnals of Neurology, 2010
- Interleukin‐6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responsesArthritis & Rheumatism, 2008
- Muscle Undergoes Atrophy in Association with Increase of Lysosomal Cathepsin Activity in Interleukin-6 Transgenic MouseBiochemical and Biophysical Research Communications, 1995